A federal judge has rejected efforts to slow the progress of a $7.25 billion class action settlement in the nationwide Roundup cancer litigation, notching a win for Roundup maker Bayer but frustrating a group of plaintiffs’ attorneys who claim the deal is unfair to cancer patients.
By Carey Gillam
Lawyers representing a man who blames his cancer on exposure to Monsanto’s Roundup weed killer are crying foul over what they say are close personal ties between a lead Monsanto lawyer and a special magistrate helping oversee the Roundup litigation.
By Carey Gillam
After brief deliberations, a St. Louis jury on Thursday sided with Monsanto in the latest Roundup cancer trial. The win puts Monsanto and its German owner Bayer AG at five trials won versus three won by plaintiffs. The jury took only a few hours to reach the defense verdict.
A St. Louis jury on Wednesday heard opening statements in a new Roundup cancer trial that is the latest in a long line-up of coming courtroom battles over allegations that Monsanto’s popular weed killer causes cancer.
A new Roundup trial is scheduled to get underway next week, as three cancer patients face off against Monsanto in the company’s former hometown of St. Louis, Missouri, alleging exposure to the company’s weedkilling chemical caused their illnesses.
Monsanto on Thursday asked a St. Louis judge to delay the start of a trial over claims brought by three men alleging exposure to Monsanto’s glyphosate-based herbicides, such as the popular Roundup brand, caused them to develop non-Hodgkin lymphoma.